logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Grifols, S.A.

GRFS

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalentā€¦ read more

Healthcare

Drug Manufacturersā€”General

14 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$9.02

Price

+1.12%

$0.10

$8.92

Previous Close

$8.97

Open

Premium

52w Discount
Market Cap

$7.631b

Mid

Price/Earnings

14.1x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

+24.5%

EBITDA Margin

+6.8%

Net Profit Margin

+13.7%

Free Cash Flow Margin
Revenue

$7.518b

+4.2%

1y CAGR

+7.4%

3y CAGR

+11.3%

5y CAGR
Earnings

$372.721m

+137.5%

1y CAGR

+110.4%

3y CAGR

+82.3%

5y CAGR
EPS

$0.55

+139.1%

1y CAGR

+74.6%

3y CAGR

+59.6%

5y CAGR
Book Value

$7.572b

$19.917b

Assets

$12.345b

Liabilities

$9.719b

Debt
Debt to Assets

48.8%

0.7x

Debt to EBITDA
Free Cash Flow

$851.185m

+60.4%

1y CAGR

+272.0%

3y CAGR

+151.4%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in EUR.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.